Page results
-
UCLH provides an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia. We provide an advanced diagnostic service and a comprehensive treatment programme for patients with different types of leukaemia.
-
UCLH is a centre of excellence in the management of patients with acute and chronic leukaemia.
-
The bone marrow transplant and haematopoietic stem cell transplant service at UCLH is the largest in Europe and provides a full range of transplant services.
-
UCLH is a designated Haemophilia Centre providing a 24/7 service for patients, including those needing treatment with blood products and clotting factor medications.
-
Thalassaemia is a group of inherited blood conditions where the part of the blood known as haemoglobin is abnormal.
-
Dr Swayne is a consultant neurologist with a special interest in neurorehabilitation and stroke.
-
Patient information for patients who are having a bone marrow biopsy.
-
This page is intended for women with a cyst or abscess of the Bartholin’s gland. It provides information on the condition and the treatment options available in our hospital.
File results
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0513 - Robotic platforms for surgery costs/ contract
-
FOI/2024/0514 - Viscosupplementation injections/ spend
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer